Mizuho analyst Joseph Catanzaro initiated coverage of Upstream Bio (UPB) with an Outperform rating and $51 price target The company’s lead program verekitug is well positioned for a positive Phase II readout in asthma in Q1, the analyst tells investors in a research note. The firm projects $2.7B in risk-adjusted 2035 worldwide sales for verekitug and expects the positive Phase II data to drive share outperformance.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UPB:
- Upstream Bio initiated with an Outperform at LifeSci Capital
- 3 Best Stocks to Buy Now, 11/26/2025, According to Top Analysts
- Promising Outlook for Upstream Bio, Inc. Driven by Verekitug’s Clinical Advancements
- Upstream Bio initiated with an Outperform at Evercore ISI
- Upstream Bio, Inc.’s Verekitug: A Promising Buy with Blockbuster Potential in Asthma and COPD Markets